Chime Biologics Won The Best Biologics CMO in Greater China Region

On September 14, 2022, Chime Biologics won the “Best Biologics CMO in Greater China Region” for the CDMO technology services with international quality standards at Biologics Contract Manufacturing ASIA 2022 in Singapore.

At Biologics Contract Manufacturing ASIA 2022, Chime Biologics was titled the “Best Biologics CMO in Greater China Region” for the CDMO technology services can satisfy the international quality standards. Dr. Zack Zheng, CTO & SVP, Chime Biologics, attended the award ceremony.

This award is a recognition of Chime Biologics for the reliable, compliant, flexible and rapid services, innovative team and operational excellence. By leveraging our innovative R&D and manufacturing capabilities, we will assist the manufacturing of biologics in the whole process from cell line development to commercial manufacturing, supporting customers to deliver affordable and accessible biologics materials that can benefit patients worldwide.

About Chime Biologics

Chime Biologics is a global leading CDMO that has introduced the first modular biopharmaceutical plant KUBio in the world to empower its partners’ success in biologics in the whole process from cell line development to commercial manufacturing. Relying on cell line development and advanced technology development from our Shanghai Innovation Center and proven success in IND-enabling through BLA filing at its Wuhan plant, Chime Biologics is providing a one-stop CMC solution for biopharmaceutical customers around the world. We share a common goal to make cutting-edge biomedicines affordable and accessible to all patients globally, fulfilling its commitment to human health.  For more information, please visit www.chimebiologics.com.